• Target disease: Leishmaniasis
  • Main partners (since project start): Daiichi Sankyo, Japan  
  • Project start: 2017
  • Funding (since project start): Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Global Health Innovative Technology (GHIT) Fund, Japan; Swiss Agency for Development and Cooperation (SDC), Switzerland.


Overall Objective:

  • Identify at least one – possibly two – progressable lead series meeting DNDi lead stage criteria for visceral leishmaniasis.



Current hit-to-lead efforts of the series identified from the Daiichi Sankyo Pharma Space Library focus on Chagas disease, but the project team submits any newly synthesized molecules to a Leishmania cross screen to assess potential.



Last update: August 2018